Library — CHDR

Search

Filter

Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics.

Kreilgaard M, Kemme MJ, Burggraaf J, Schoemaker RC, Cohen AF

Pharmaceutical research, 2018 Dec; 18(5):593-9

View publication
Personalized omalizumab treatment improves clinical benefit in patients with chronic spontaneous urticaria.

Niemeyer-van der Kolk T, van Maaren MS, van Doorn MBA

The Journal of allergy and clinical immunology, 2018 Nov

View publication
Complement Activation in Inflammatory Skin Diseases.

Giang J, Seelen MAJ, van Doorn MBA, Rissmann R, Prens EP, Damman J

Frontiers in immunology, 2018 Jul

View publication
Comprehensive, Multimodal Characterization of an Imiquimod-Induced Human Skin Inflammation Model for Drug Development.

van der Kolk T, Assil S, Rijneveld R, Klaassen ES, Feiss G, Florencia E, Prens EP, Burggraaf J, Moerland M, Rissmann R, van Doorn MBA

Clinical and translational science, 2018 Jul

View publication
Topical ionic contra-viral therapy comprised of digoxin and furosemide as a potential novel treatment approach for common warts.

van der Kolk T, Dillingh MR, Rijneveld R, Klaassen ES, de Koning MNC, Kouwenhoven STP, Genders RE, Bouwes Bavinck JN, Feiss G, Rissmann R, Burggraaf J

Journal of the European Academy of Dermatology and Venereology : JEADV, 2017 Sep

View publication
Injection site reactions after subcutaneous oligonucleotide therapy.

van Meer L, Moerland M, Gallagher J, van Doorn MB, Prens EP, Cohen AF, Rissmann R, Burggraaf J

British journal of clinical pharmacology, 2017 Sep; 82(2):340-51

View publication
Morphological characteristics and HPV genotype predict the treatment response in cutaneous warts.

Hogendoorn GK, Bruggink SC, de Koning MNC, Eekhof JAH, Hermans KE, Rissmann R, Burggraaf J, Wolterbeek R, Quint KD, Kouwenhoven STP, Bavinck JNB

The British journal of dermatology, 2017 Jul

View publication
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis.

Balak DM, van Doorn MB, Arbeit RD, Rijneveld R, Klaassen E, Sullivan T, Brevard J, Thio HB, Prens EP, Burggraaf J, Rissmann R

Clinical immunology (Orlando, Fla.), 2016 Dec

View publication
Pharmacokinetics of oral fumarates in healthy subjects.

Litjens NH, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, van Dissel JT, Thio HB, Nibbering PH

British journal of clinical pharmacology, 2004 Oct; 58(4):429-32

View publication

«
1
2
»